Medical Education Grants

Medical Education Grants

Jazz Pharmaceuticals (Jazz) is committed to improving patient outcomes and providing support in compliance with local regulations.

Therapeutic Areas of Interest

Oncology

Acute Myeloid Leukemia (AML)
  • The role of intensive chemotherapy in the treatment of secondary AML
  • Identification and timely, actionable diagnosis of high-risk AML subsets (e.g., AML-MRC, tAML)
  • Different technologies for the delivery of secondary AML treatments
    • Treatment of secondary AML to include:
      • Efficacy
      • Safety
      • Impact on quality of life
      • Depth of response, real world data and long-term outcomes
  • Appropriate management of secondary AML patients in the in-patient and out-patient setting
  • The AML treatment paradigm (e.g., induction, consolidation, combination therapy, maintenance therapy) and patient management
  • Clinical and economic burden of secondary AML
Veno Occlusive Disease (VOD)
  • Recognition, incidence, risk factors, diagnosis and early intervention of VOD/SOS including in the non-transplant setting
  • VOD/SOS diagnostic criteria, diagnostic techniques, radiologic findings and severity grading in both adult and pediatric patients
  • Pathophysiology, progressive nature and life-threatening complications of advanced VOD/SOS and other endothelial related complications
  • Efficacy, safety and mechanism of action of current therapies and patient management for the treatment of VOD/SOS
  • Clinical and economic burden of VOD/SOS and other post-transplant complications associated with endothelial cell damage
  • Efficacy and safety of current therapies and patient management for COVID-19 related ARDS and other endotheliitis
Acute Lymphoblastic Leukemia (ALL)
  • The biology of immune response, differentiation and management of asparaginase hypersensitivity reaction vs. infusion reaction and the impact and burden on safety and efficacy
  • The importance of completing treatment and potential safety or other concerns associated with current clinical mitigation strategies for hypersensitivity reactions
  • Recognition and management of asparaginase toxicities in the adult/young adult population
  • Management of pediatric and adult/young adult ALL/LBL with asparaginase (e.g., monitoring, PK, safety, clinical value)
  • Pediatric inspired protocols in the adult/young adult population
  • The efficacy and clinical benefits of new asparaginase formulation in ALL/LBL
  • Asparaginase therapies and combinations beyond ALL/LBL